Cytokinetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

498

Employees498

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

498

Employees498

CYTK Key Statistics

Market cap

3.57B

Market cap3.57B

Price-Earnings ratio

-5.62

Price-Earnings ratio-5.62

Dividend yield

—

Dividend yield—

Average volume

3.16M

Average volume3.16M

High today

$30.05

High today$30.05

Low today

$29.31

Low today$29.31

Open price

$30.04

Open price$30.04

Volume

2.31M

Volume2.31M

52 Week high

$61.40

52 Week high$61.40

52 Week low

$29.31

52 Week low$29.31

CYTK News

TipRanks 18h

Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology

Cytokinetics (CYTK) announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium on Friday, May 30th, 202...

TipRanks 2d

Cytokinetics’ MAPLE Trial Results: Hold Rating Amid Uncertainties in Secondary Outcomes and Market Adoption

Analyst Jason Zemansky of Bank of America Securities maintained a Hold rating on Cytokinetics (CYTK – Research Report), retaining the price target of $45.00. P...

TipRanks 3d

Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position

Needham analyst Serge Belanger maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $72.00. Protect Your Portfolio...

Analyst ratings

86%

of 22 ratings

Buy

86.4%

Hold

13.6%

Sell

More CYTK News

TipRanks 3d

Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Cytokinetics (CYTK – Research Report). The associated price target remains the s...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.